CIP2A in Cancer: Molecular Mechanisms, Signalling Networks and Clinical Implications
Biomolecules · 18.11.2026 · 16 (11) · 1677
DOI: 10.3390/biom16111677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 18.11.2026. Verfasst von Abigail H. Burnett und 2 weiteren Autor:innen. Die Arbeit nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Chester Research and Knowledge Exchange Institute.
Abstract (Originalsprache)
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that is frequently overexpressed in many cancers and can be associated with cancer progression, poor prognosis, and treatment resistance. CIP2A was initially characterised as an inhibitor of protein phosphatase 2A (PP2A), thereby inhibiting the dephosphorylation and degradation of the transcription factor c-Myc. However, more recent evidence suggests that CIP2A has broader functions in cell cycle progression, genomic stability, and DNA damage repair. CIP2A is regulated at multiple levels, including transcriptional, post-transcriptional and post-translational mechanisms, allowing integration with several oncogenic signalling pathways. Elevated CIP2A expression has been reported in numerous haematological and solid malignancies, where it is frequently associated with poor clinical outcomes. Growing evidence supports the use of CIP2A as a prognostic biomarker, and its central role in tumour biology has established the CIP2A-PP2A interaction as a promising therapeutic target. Although challenges remain, including incomplete structural characterisation and the absence of clinically approved CIP2A-targeted therapies, continued research in biomarker development and drug discovery highlights the potential of CIP2A in personalised cancer treatment to improve patient outcomes.
Förderung
- University of Chester Research and Knowledge Exchange Institute
Zitieren
APA
Burnett, A. H., Basabrain, A. A., & Lucas, C. M. (2026). CIP2A in Cancer: Molecular Mechanisms, Signalling Networks and Clinical Implications. Biomolecules, 16(11), 1677. https://doi.org/10.3390/biom16111677
Vancouver
Burnett AH, Basabrain AA, Lucas CM. CIP2A in Cancer: Molecular Mechanisms, Signalling Networks and Clinical Implications. Biomolecules. 2026;16(11):1677. doi:10.3390/biom16111677
BibTeX
@article{Burnett2026,
author = {Burnett, Abigail H. and Basabrain, Ammar A. and Lucas, Claire M.},
title = {CIP2A in Cancer: Molecular Mechanisms, Signalling Networks and Clinical Implications},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {11},
pages = {1677},
doi = {10.3390/biom16111677}
}
EUVIMED